Klinické štúdie Nadváha v štáte Minnesota
13 štúdií pre Nadváha hľadá účastníkov v zariadeniach v štáte Minnesota.
Mestá v štáte Minnesota
Oficiálny text štúdie (anglicky)
AMAZE 2: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight
- International Diabetes Center, Minneapolis
Prebieha náborFáza 3
Vek 18 a viac · Všetky pohlavia · Aktualizované 30. 9. 2026 · NCT07533175A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight
- University of Minnesota, Minneapolis
- Synexus Clinical Research US-MN, Richfield
Prebieha náborFáza 3
Vek 8 až 18 · Všetky pohlavia · Aktualizované 30. 9. 2026 · NCT07253285A Study to Learn About the Monthly Dosing Study Medicine Called Berobenatide in Adults With Breathing Problems During Sleep and Overweight or Obesity Who Use a Breathing Machine (PAP) (VESPER-OSA 1)
- Headlands Research - Twin Cities, Maplewood
Prebieha náborFáza 3
Vek 18 a viac · Všetky pohlavia · Aktualizované 29. 9. 2026 · NCT07823608A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity
- Headlands Research-Twin Cities, Maplewood
Prebieha náborFáza 3
Vek 18 a viac · Všetky pohlavia · Aktualizované 28. 9. 2026 · NCT07794579A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)
- University of Minnesota Masonic Children's Hospital, Minneapolis
- Mayo Clinic - PIN, Rochester
- Children's Minnesota Pediatric Endocrinology Clinic & McNeeley Diabetes Center, Saint Paul
Prebieha náborFáza 3
Vek 6 až 17 · Všetky pohlavia · Aktualizované 24. 9. 2026 · NCT06672549A Study of Eloralintide (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or Overweight
- Headlands Research-Twin Cities, Maplewood
Prebieha náborFáza 3
Vek 18 a viac · Všetky pohlavia · Aktualizované 22. 9. 2026 · NCT07369011Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
- Fairview Health Services M Health Fairview St Johns Hospital, Maplewood
- Minneapolis Heart Institute Foundation, Minneapolis
Prebieha náborFáza 3
Vek 45 až 99 · Všetky pohlavia · Aktualizované 22. 9. 2026 · NCT07037433A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes
- AURORA-2 Clinical Site, Mankato
Prebieha náborFáza 3
Vek 18 a viac · Všetky pohlavia · Aktualizované 16. 9. 2026 · NCT07743450A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes
- International Diabetes Center At Park Nicollet, Minneapolis
Prebieha náborFáza 3
Vek 18 a viac · Všetky pohlavia · Aktualizované 14. 9. 2026 · NCT07351045A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)
- ACCOMPLISH-2 Research Site, Mankato
- ACCOMPLISH-2 Research Site, Minneapolis
Prebieha náborFáza 3Vítaní zdravých dobrovoľníkov
Vek 18 až 79 · Všetky pohlavia · Aktualizované 11. 9. 2026 · NCT07654374Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)
- ACCOMPLISH-1 Research Site, Mankato
- ACCOMPLISH-1 Research Site, Richfield
Prebieha náborFáza 3
Vek 18 až 79 · Všetky pohlavia · Aktualizované 10. 8. 2026 · NCT07654361A Proof-of-Concept Study to Evaluate Topical-Lingual Semaglutide in Adults With Obesity
- Clinical Research Institute of Minnesota, Minneapolis
Prebieha náborFáza 4
Vek 18 až 65 · Všetky pohlavia · Aktualizované 27. 7. 2026 · NCT07728383Functional Improvement in OSA and COPD With a Telehealth LifeStyle and Exercise Intervention
- Minneapolis VA Health Care System, Minneapolis
Prebieha nábor
Vek 18 a viac · Všetky pohlavia · Aktualizované 22. 7. 2026 · NCT06390345Z ClinicalTrials.gov, dáta načítané 5. 10. 2026. Každá štúdia má vlastné kritériá oprávnenosti; tím štúdie rozhoduje o účasti.